Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Just to add to the credibility talk
View:
Post by Bucknelly21 on Jan 08, 2021 12:48pm

Just to add to the credibility talk

I will say one thing, Thtx has not taken on anything that seems to have not worked out as far as r&d. Sales clearly not their strong point but gettting projects to the finish line is definitely very much their forte. After yesterday's pr I felt like all the doubts I had about a lot of where they were headed are put to rest. And like spceo and wino ect have pointed out its only a matter of time before that valuation that we all know is right comes to life. It makes me feel that when they play things so close to the chest ie nash and oncology they already have a good idea of where it's heading. I would say you can back the truck up for any price under double digits this year. Oncology will be a home run as Thtx has proven they don't get involved with a project without feeling extremely confident in the outcome as far as dealing with the agencies. Would be nice to see a better reaction to yesterday but it's on its way. I was always agreeing with everyone saying be patient because I was trying to cling onto some hope for this company because I had such a big position relative to my situation. But now I actually really think that this has a good chance to be one of those 5 chances in the market that a person has to really do some damage. Analysis on this board has been pretty spot on, only a matter of time before they run out of Cheetos and have to do some actual work. 2021 is the breakout
Comment by qwerty22 on Jan 09, 2021 8:50pm
I think this is a good example of why maybe oncology is not a slam dunk but a risky 3 pointer. https://www.evaluate.com/vantage/articles/news/trial-results/mersana-starts-lose-its-shine Targeted ovarian cancer using ADC. Interesting to look at that table of data flow at conferences in the article and compare it to SP. The stock jumped to $1billion on the first 20 patients efficacy data in ...more  
Comment by Wino115 on Jan 10, 2021 9:19am
Fair analogy and we should be cautious on anything going into humans for the first time. I would point out one interesting difference THTX has too.  If I recall, both Taxol and Rubicin are still used a lot in the overall treatment lists for various cancers.  So one alternative sign of efficacy is if THTX PDCs are a lot better than just the plain old cytotoxin. If better and safer, you ...more  
Comment by scarlet1967 on Jan 10, 2021 9:43am
Here it is. https://pubs.rsc.org/en/content/articlehtml/2021/cs/d0cs00556h
Comment by jeffm34 on Jan 10, 2021 10:21am
Interesting reading the Mersana article and the analysts reaction to bad news from their trials.  They have bad news and the analysts try and keep a positive outlook despite the data. TH has good news (Nash phase 3 trial to proceed) and the analysts throw cold water on it.  
Comment by scarlet1967 on Jan 10, 2021 10:52am
What would they do when they recommend a company to their clients and the company have a set back they would try to brush it off not admitting they were wrong. Now we have the opposite situation as for THTX the analysts covering the company have been refusing to account for their R&D programs or not giving it the credit it deserves so when the company comes out and clearly proof them wrong ...more  
Comment by scarlet1967 on Jan 10, 2021 11:00am
Proove them wrong, the autocorrection of Stockhouse is sometime is annoying
Comment by jfm1330 on Jan 10, 2021 10:38am
Oncology is obviously not a slam dunk, it would be foolish to think it is. That being said the Mersana example given is very different. It uses ADC, not PDC, and a proprietary drug (auristatin) that is highly toxic, so toxic it cannot be used as a single agent, and sometning they call Dodalock technology that prevent their highly toxic drug to diffuse a lot to neighboring cells that may not be ...more  
Comment by qwerty22 on Jan 10, 2021 11:50am
Comment by qwerty22 on Jan 10, 2021 5:40pm
Of course antibodies are different to peptides. One peptide is different to another peptide and its interaction with its target is different in many ways. None of these examples , including your ones, are intended to be exact mirrors of thtx's program but they all are instructive. Antibodies are by far the largest segment of the target cancer sector and it would be crazy to ignore them. As it ...more  
Comment by Copperkettle08 on Jan 10, 2021 6:08pm
Not sure how posting  about radio nucleoside helps anyone on this Message Board!! Maybe jmf and others should join as medical board or get a job at ThTX lab   
Comment by Wino115 on Jan 10, 2021 9:23pm
Helpful distinction.  Hence, your idea with a nuclear identifying agent. Have you ever emailed Marsolais with your inquiry and suggestion? He'd probably reply if you pass it by IR.